Non-adherence has historically been blamed on the patients themselves. However, a broad industry shift towards patient centricity and a great appreciation of the behavioural barriers means that the focus of responsibility is shifting to healthcare practioners, the government and pharmaceutical companies.
Patient’s automatic decision-making processes exert a strong influence on behaviour and therefore understanding the personal and situational barriers in the use of medication is crucial to combat the adherence problem effectively.
Our paper provides a framework for thinking about adherence through patient behaviour, looking at four categories: motivation, ability, physical context and social context. These are overlaid with the three stages of adherence to give a holistic understanding of the problem at hand.
With this framework, we can begin to create bespoke interventions which speak to individuals, allowing a patient-centric and more informed approach to tackling the adherence challenge.
The link below will take you to the full report
ESG: A hidden driver of brand success in healthcare
Global concerns are usually dominated by immediate issues. But when we ask what worries the world, our data show that climate change, poverty and social inequality remain the constant and significant worries that unite people across the globe. But, what does ESG mean for life science companies and the healthcare industry?